Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBP-EC01 (Locus Biosciences)
- Development stage
- Unknown
- Lead developer
- Locus Biosciences
- Modality
- CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
- Administration
- Intravenous, Intraurethral, Intravesicular
01
Overview
LBP-EC01 is an investigational **CRISPR-based bacteriophage biologic** developed by Locus Biosciences for treatment of **Escherichia coli urinary tract infections**. It consists of a **genetically enhanced six-bacteriophage cocktail** engineered with **CRISPR-Cas3** payloads that, after phage infection of susceptible *E. coli*, drive extensive degradation of bacterial DNA and thereby increase bacteriophage killing efficiency while sparing non-target members of the microbiome. The program has been described as a precision antimicrobial recombinant phage therapy and has reported proof-of-mechanism in a randomized placebo-controlled clinical trial in UTI.
- Other names
- CRISPR-Cas3-enhanced bacteriophageCRISPR-Cas-3-enhanced bacteriophageCRISPR-Cas 3-enhanced bacteriophagecrPhageCRISPR-Cas3-enhanced bacteriophage cocktailCRISPR-Cas-3-enhanced bacteriophage cocktailCRISPR-Cas 3-enhanced bacteriophage cocktail
02
Targets
bacterial dsDNA (Bacterial double-stranded DNA)
Beyond the preview
Go deeper on LBP-EC01 (Locus Biosciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBP-EC01 (Locus Biosciences).